HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Symrise peptides available

This article was originally published in The Rose Sheet

Executive Summary

Ingredient supplier's purchase of a 20% stake in Louisiana-based Therapeutic Peptides Inc. gives it exclusive distribution rights to "ultra-innovative group of active ingredients known as peptides," used in personal-care products for their anti-microbial and anti-aging benefits, as well as to stimulate hair growth, firm says Aug. 19. "We are delighted to be able to integrate these modern and very effective ingredients in our portfolio. With TPI, we have found a partner who is developing these ingredients at a scientifically exalted level and can offer ample expertise in this field," says Symrise's Dr. Klaus Stanzl, president scent & care, life essentials, who has been elected to TPI's supervisory board. Symrise recently expanded its organic botanicals offering to include Bayliss Ranch's USDA-certified AllPlant Essence line (1"The Rose Sheet" Aug. 18, 2008, p. 7)

You may also be interested in...



Symrise Grows Organic Portfolio With USDA-Certified AllPlant Essence Line

Ingredient supplier Symrise has extended its organic botanicals offering to include a line of water-soluble plant extracts certified organic by the U.S. Department of Agriculture's Natural Organic Program

STADA Strengthens Specialty Partnership Role Via US Filing

STADA Strengthens Specialty Partnership Role Via US Filing

Bayer's Job Cuts And Flat 2021 Sales Outlook Disappoint

Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel